HotPennyStockNews.com is devoted to fetch you the most exclusive stocks in the market today. Apart from scanning the markets for the most underrated stocks. We propel those victors directly to your email inbox first ahead of the rest of the marketplace gets a prospect.
Los Angelas, CA -- (SBWIRE) -- 09/28/2012 -- Zale Corporation (NYSE:ZLC) reported EPS of -0.853. For the Current Fiscal year, the company is expected to report EPS of 0.27. For the Next Quarter and Next Year, the company is expected to report EPS of 1.03 and 0.49 respectively. At Current Market Price, ZLC is in distance of +36.15% from its 50-day Moving Average price of $5.002 and +106.17% from its 200-day Moving Average price of $3.3031. Zale Corporation (ZLC): This stock has shown some good movement in the recent passed, breaching its $4 mark late last month. Its CEO Theo Killion bought 4000 shares at the average price of $6.306. The stock is clearly in the bullish phase as it is trading above its short-term 20-days EMA and long-term 50-days EMA prices and its CEO's current purchase shows that the upward momentum is likely to continue for the stock. Operating in the luxury retail segment, the company had been going through tough times.
Should Investors Buy or Sell ZLC This Range? Find Out Here
Gevo, Inc. (NGM:GEVO) is very active today and traded among $1.82 - 2.02 with total traded volume of 1679427 shares. At a current price of 2.00, GEVO is +0.16 - +8.70% from the previous close of $1.84. Moreover, At Current Market Price, GEVO is in distance of -41.58% from its 50-day Moving Average price of $3.4234 and -66.85% from its 200-day Moving Average price of $6.0335. Gevo, Inc. (NASDAQ:GEVO) is down 7.71% today at $1.98. GEVOhas traded 2.3 million shares so far today, well above its daily average of 670 thousand shares. GEVOshares are falling again today following news it was shifting to ethanol from biobutanol at its plant in Minnesota for the near term. The company has a market cap of 77.48 million.
Should Investors Buy or Sell GEVO This Range? Find Out Here
Achillion Pharmac (NasdaqNM:ACHN) is +0.805 - +8.48% from the previous close of $9.49. It traded among $9.76 - 11.01 with total traded volume of 6258743 shares. Keep a close eye on ACHN, as the stock has been showing unusual moves over the passed weeks. At Current market price, ACHN has recovered +170.21% from its 52-week Low of 3.81 and has Pulled back -20.50% from its 52-week high of 12.95. Achillion Pharmaceuticals, Inc.(NASDAQ:ACHN) shares jumped 5.48% to $10.01 after the company announced positive proof-of-concept results with ACH-3102, a second-generation pan-genotypic NS5A inhibitor being developed for the treatment of chronic hepatitis C viral infections (HCV). Administration of a single-dose of ACH-3102 to genotype 1a HCV-infected subjects resulted in a mean maximum 3.74 log10 reduction in HCV RNA (range 2.9 – 4.6 log10). Significant reductions in HCV RNA were achieved in subjects with resistant variants at baseline, including L31M and Y93C variants.
Can ACHN Breaks Its Previous High : Find Out Here
Neuralstem, Inc. (AMEX:CUR) reported EPS of -0.209. For the Current Fiscal year, the company is expected to report EPS of -0.20. For the Next Quarter and Next Year, the company is expected to report EPS of -0.05 and -0.21 respectively. At Current Market Price, CUR is in distance of +56.36% from its 50-day Moving Average price of $0.8314 and +38.03% from its 200-day Moving Average price of $0.9419. Neuralstem Inc. (NYSEAMEX: CUR : 1.3, 0.101), which develops treatments for central nervous system disease, said it has received approval to begin ischemic stroke clinical trial in China with its spinal cord stem cells. The company, through its subsidiary - Neuralstem China (Suzhou Neuralstem Biopharmaceutical Co. Ltd.) - will begin a clinical trial to treat motor deficits due to ischemic stroke with its spinal cord stem cells at BaYi Brain Hospital in Beijing. The trial approval includes a combined phase 1 and 2 design, and will test direct injections into the brain of NSI-566, the same cell product tested by Neuralstem in a recently-completed phase IALS trial in the United States.
Should Investors Buy or Sell CUR This Range? Find Out Here
Neither HotPennyStockNews.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor or broker dealer in any jurisdiction whatsoever and none of the information provided by HotPennyStockNews.com, owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or an investment recommendation. HotPennyStockNews.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through HotPennyStockNews.com. Investing in securities is speculative and carries a high degree of risk and no investment should be made unless you can afford to lose your entire investment. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein..
Contact Us: 888-4-SBWIRE (US) - 920-321-1250 (International)